Pfizer says clotting drug's once-weekly dose reduces bleeding rate
July 16 (Reuters) - Pfizer Inc said a once-weekly dose of its drug, already approved for on-demand treatment of a blood clotting disorder, reduced bleeding rates in patients in a late-stage study.
Hemophilia B patients taking the drug, BeneFIX, once a week showed a statistically significant reduction in the annualized bleeding rate compared with those administered the drug on demand. (Reporting by Shailesh Kuber in Bangalore; Editing by Kirti Pandey)
- Police seek motive in fatal Washington state school shooting
- Wall St. finally turning on Amazon as Bezos magic fades
- Two deputies killed, two others hurt in California shooting spree
- Easter Island's ancient inhabitants weren't so lonely after all
- Medical worker quarantined in New Jersey under new Ebola safeguards |